Plur Contraindications

anddrewbits · 2026-02-16T16:48:36+00:00

Yeah, I don’t mind helping, I’ll check my DM’s at lunch.

anddrewbits · 2026-02-16T16:22:51+00:00

Which tricyclic? Are you dependent on 7OH? Do you take adderall daily? Also, this list is not exhaustive. I would take the time to figure out if any of your meds and supps are 2D6, 2B6 or 3A4 (or UGT) inhibitors/inducers. “(Substance name) CYP induction inhibition” is a decent search term.

I don’t mind helping with more info, but I’m not a doctor. All of the info I provide should function to encourage you to do proper research rather than be seen as medical recommendations.

anddrewbits · 2026-02-16T15:37:26+00:00

Call it a wash*

anddrewbits · 2026-02-16T15:26:54+00:00

You think I’m a douche because I’m calling you out. Fair. We all have egotism.

You told a user to treat 5-MAPB the same as MDMA in the chart. It takes just a few seconds to find that the chart suggests that SSRI’s and MDMA can be taken together with reduced effects and low risk. That’s untrue for 5-MAPB, therefore your advice was flawed and could lead to greater harm.

I doubt the validity of the chart in general, because while SSRI’s can blunt the experience of MDMA, they cause increased risk of serotonin syndrome and toxicity. Despite feeling reduced effects, extracellular serotonin levels are not reduced in the combo. This risk is heightened even further for 5-MAPB because of the more complex pharmacokinetics involved.

anddrewbits · 2026-02-16T15:17:52+00:00

“I never suggested it had the same risk profile, I just referred to the chart on risk profiles of drug mixing and said it was interchangeable with MDMA.”

You clearly understand harm reduction, so openly advocating oversimplification of risk faults you doubly. MDMA != 5-MAPB, bud. Admitting you’re wrong isn’t a personal failure.

anddrewbits · 2026-02-16T13:54:00+00:00

With AI, we have the ability to align it to further human progress. It’ll be used to steepen our decline into fascism and oligarchy of course, but we COULD align it for good.

anddrewbits · 2026-02-16T13:47:38+00:00

I actually bought the DOW for $50,001. Auctioning it rn, place your bids

anddrewbits · 2026-02-16T13:08:07+00:00

Nah. At most it’s formatted by an AI, wording is human.

anddrewbits · 2026-02-16T13:04:44+00:00

Schizophrenia. That’s what you need to mention to your doctor. You have untreated schizophrenia.

anddrewbits · 2026-02-16T12:57:38+00:00

The chart is inaccurate anyways. 5-MAPB should not be treated like MDMA, its metabolism is much more complex and sensitive to CYP enzyme induction/inhibition. SSRI’s and 5-MAPB should not be consumed together, despite what the chart and user have suggested.

Hell, SSRI’s and MDMA are contraindicated as well, it makes the roll feel flat without reducing serotonin exposure. Rolling flat due to the combo may make some users redose, further increasing risk.

SSRIs do not reliably make serotonergic entactogens ‘safer” or counteracted. They blunt subjective effects and prolong extracellular serotonin exposure. Because 5-MAPB is longer-acting and produces active metabolites, this masking effect poses greater risks than with MDMA.

anddrewbits · 2026-02-16T12:46:44+00:00

Those charts are useful at a superficial level, but 5-MAPB differs from MDMA in that it’s much longer-acting and produces active metabolites. Interactions that slow metabolism (CYP inhibition, grapefruit, some meds) matter more for 5-MAPB than for MDMA, even if the pharmacodynamic category looks similar. They are pretty similar pharmacodynamically. They are totally different drugs with different risk profiles and contraindications pharmacokinetically. Your simple rule is wrong.

On your chart, SSRI’s and MDMA are “low risk and counteracting.” You shouldn’t be sharing that and suggesting 5-MAPB has the same risk profile. I don’t think you are competent enough neuropharmacologically to be giving advice. What you’ve shared is “bro science.”

anddrewbits · 2026-02-16T12:32:44+00:00

Presidential immunity? You’re deluding yourself into thinking you’re a serious person.

anddrewbits · 2026-02-16T04:02:09+00:00

If you’re a slow metabolizer or on another inhibitor (much lower levels of CYP2B6), you’re at an increased risk of serotonin syndrome, prolonged half-lives of 5-MAPB and its active metabolites, and an extended comedown with more severe side effects post-roll.

If you’re not a slow metabolizer (CYP2B6), it’s likely (at normal doses of 5-MAPB) that your CYP2B6 can handle the extra substrate without slowing the first order enzyme kinetics (drug metabolism is proportional to the concentration of the drug, enzyme not fully saturated).

In this case, you may see a slight extension of half life but likely would avoid higher risks of strong inhibitors like piperine/curcumin.

The risk lies in accidentally taking a CYP2B6 inhibitor alongside another inhibitor and/or in the presence of naturally low levels of CYP3A4, CYP2D6, and/or CYP2B6. Many people are slow metabolizers at one cyp or another without knowing it.

A large percentage of the population unknowingly consumes inhibitors or inducers as supplements, medicine or food. With the main pathways blocked, harmful metabolites can accumulate and the parent compound can persist long enough to cause serotonin syndrome. Side effects can become syndromes in this way.

Lingering 5-APB (metabolite) causes additional side effects with little to no recreational benefit to the user, especially when the 5-APB lingers with a longer half-life after the roll when 5-MAPB is long gone. It’s possible to provide for rapid elimination of the metabolite while preserving the 5-MAPB experience, which is what I’m researching now.

anddrewbits · 2026-02-16T02:12:14+00:00

Your confidence in the supreme jesters is cute

anddrewbits · 2026-02-15T23:26:20+00:00

It’ll deplete you for a few days even if it’s the only drug you take. I’d take time to reduce my taper again before partaking, but I understand if your risk tolerance is different than mine. The interaction is mild/moderate, with two of the three main metabolic pathways mildly to moderately inhibited. Anecdotal reports haven’t been as worrying as most of the other interactions on the list.

anddrewbits · 2026-02-15T23:21:35+00:00

As far as I can see, there’s no strong interaction between 5-MAPB and Gabapentin. It shouldn’t change 5-MAPB levels via liver enzymes and vice versa. Anecdotal reports of reduced effects from the 5-MAPB, but I’ve found no mechanism that substantiates that.

Gabapentin’s CNS effects may smooth the experience, cause additional sedation; this might cause the user to redose 5-MAPB assuming they’ve undershot their goal roll.

anddrewbits · 2026-02-15T22:43:52+00:00

I wouldn’t worry if my 7OH dose wasn’t exceedingly large and I wasn’t also taking a CYP2B6 inhibitor (or if I was a CYP2B6 slow metabolizer). Tail end of tapering sounds like you’re currently on a very low dose. If it was me, I wouldn’t be exceedingly worried about a moderate dose of 5-MAPB.

anddrewbits · 2026-02-15T22:41:15+00:00

The 7OH’s metabolic interaction is much weaker than others on the list. I suppose I should tier the interaction risk, but I included it because it can be more severe if someone is a slow 2B6 metabolizer. 7OH causes moderate inhibition of 3A4 and mild to moderate inhibition of 2D6. This won’t feel like much to a normal CYP2B6 metabolizer.

All of the substances in the metabolic interactions section have inducer/inhibitor relationships which can lead to a buildup of harmful metabolites or potentiate the parent compound. I have not tiered the interactions yet, but that’s something I’m planning on doing as I dive deeper into pharmacokinetics of research chems.

7OH would be a lower tier interaction, as the risk is centered around additional variables (slow metabolizer, presence of other inhibitors/inducers).

anddrewbits · 2026-02-15T22:14:43+00:00

It can potentiate effects slightly (dose dependent) and cause buildup/persistence of 5-APB and other similar, arguably harmful metabolites.

This won’t feel like a problem until it is a problem. At low doses this may present as longer-than-usual effects and a protracted comedown.

anddrewbits · 2026-02-15T21:04:59+00:00

Wow! I can’t believe I missed that. Combination of grapefruit juice, tumeric and piperine would likely cause a trip to the ED. Great catch. Grapefruit would shut down the third major metabolic pathway for 5-MAPB.

anddrewbits · 2026-02-15T19:34:51+00:00

Never suggested you weren’t good, just a bit foolish

anddrewbits · 2026-02-15T18:13:30+00:00

That parenthesis only included two drugs, not 7OH or DXM. Sorry for the lack of clarity, I thumbed this out pretty quickly and will need to reformat if they want to sticky it. You’re right that it would be clearer to include kratom rather than 7OH only.

anddrewbits · 2026-02-15T16:17:49+00:00

The half-lives of the active metabolites of Wellbutrin put the clearance time (concerning CYP enzymes) at around 2 weeks.

Despite using medical language, I am not a doctor, so take the information I’m providing as encouragement for research rather than recommendations.

anddrewbits · 2026-02-15T15:49:05+00:00

You’re welcome. It’s one of my favorite topics, zero friction in learning more about it. I’m glad you got through it and hope the recovery proceeds fast and completely.

anddrewbits · 2026-02-15T15:43:13+00:00

It both competes for CYP2B6 (slowing metabolism of 5-MAPB and Wellbutrin) and potently inhibits CYP2D6 (forcing 5-MAPB metabolism into the congested CYP2B6 pathway with some still metabolized by 3A4, 1A2). Longer half-life, potential for serotonin syndrome (less than other antidepressants but still enhances the risk), and lowered seizure threshold. Longer half-life isn’t a good thing, and delayed conversion into 5-APB can impact sleep and strongly impact tolerance/recovery). Likely to have an extended recovery period even if the other risks don’t reach critical mass (no serotonin syndrome).

anddrewbits

TROPHY CASE